mAbxience will manufacture the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme for the treatment of Fabry disease.
ExoXpert will operate the ExoPulse platform to serve demand from exosome developers for R&D-grade exosome vials as well as GMP manufacturing capabilities.
The biologics CDMO selected for a given product or program is critical to an innovator’s ability to deliver a drug product safely, on time, and on budget.
While crafting a RFP to capture the information innovators need to select a CDMO partner has always been critical; it has grown increasingly complicated.
Andrew Handorf, Director, Proposals, Scorpius BioManufacturing
Small and mid-size biopharmaceutical companies need an experienced CDMO that can help them accelerate their products from concept to treatment more than ever
This white paper explores the various types of tech transfer from preclinical to commercial stages and proposes strategies to successfully foster innovation.
Kishore Hotha, VP Global Analytical R&D - Veranova